Therefore, our study provides a theoretical basis for overcoming TKI resistance in NSCLC by identifying RNF25 as a clinical target for the combination therapy of NSCLC cells that harbor activating EGFR mutations. The gene discussed is RNF25; the disease is non-small cell lung carcinoma.